The impact of antimicrobial resistance on induction, transmission and treatment of Clostridium difficile infection
Stacey Hong A B , Daniel R Knight A and Thomas V Riley A B C D E
+ Author Affiliations
- Author Affiliations
A Medical, Molecular and Forensic Sciences, Murdoch University, Murdoch, WA 6105, Australia
B School of Biomedical Sciences, The University of Western Australia, Queen Elizabeth II Medical Centre, Nedlands, WA 6009, Australia
C School of Medical and Health Sciences, Edith Cowan University, Joondalup, WA 6027, Australia
D Department of Microbiology, PathWest Laboratory Medicine, Queen Elizabeth II Medical Centre, Nedlands, WA 6009, Australia
E Tel: +61 8 6457 3690, Email: thomas.riley@uwa.edu.au
Microbiology Australia 40(2) 77-81 https://doi.org/10.1071/MA19022
Published: 18 April 2019
Abstract
Clostridium difficile infection (CDI) of the gastrointestinal (GI) tract is a potentially life-threatening disease that has surpassed multi-drug-resistant Staphylococcus aureus as the commonest antimicrobial-resistant organism associated with healthcare1. This obligate anaerobic spore-forming Gram-positive bacillus colonises the GI tract and its numbers increase after disruption of the commensal GI microbiota often induced by exposure to antimicrobial agents2. Paradoxically, the disease that may follow its outgrowth necessitates further antimicrobial treatment. Already a major challenge to infection prevention and control strategies, there are indications that C. difficile is developing further resistance to currently used antimicrobial agents.
References
[1] Miller, B.A. et al. (2011) Comparison of the burdens of hospital-onset, healthcare facility-associated Clostridium difficile infection and of healthcare-associated infection due to methicillin-resistant Staphylococcus aureus in community hospitals. Infect. Control Hosp. Epidemiol. 32, 387–390.| Comparison of the burdens of hospital-onset, healthcare facility-associated Clostridium difficile infection and of healthcare-associated infection due to methicillin-resistant Staphylococcus aureus in community hospitals.Crossref | GoogleScholarGoogle Scholar | 21460491PubMed |
[2] Freeman, J. et al. (2010) The changing epidemiology of Clostridium difficile infections. Clin. Microbiol. Rev. 23, 529–549.
| The changing epidemiology of Clostridium difficile infections.Crossref | GoogleScholarGoogle Scholar | 20610822PubMed |
[3] Slimings, C. and Riley, T.V. (2014) Antibiotics and hospital-acquired Clostridium difficile infection: update of systematic review and meta-analysis. J. Antimicrob. Chemother. 69, 881–891.
| Antibiotics and hospital-acquired Clostridium difficile infection: update of systematic review and meta-analysis.Crossref | GoogleScholarGoogle Scholar | 24324224PubMed |
[4] Debast, S.B. et al. (2014) European Society of Clinical Microbiology and Infectious Diseases: update of the treatment guidance document for Clostridium difficile infection. Clin. Microbiol. Infect. 20, 1–26.
| European Society of Clinical Microbiology and Infectious Diseases: update of the treatment guidance document for Clostridium difficile infection.Crossref | GoogleScholarGoogle Scholar | 24118601PubMed |
[5] Lessa, F.C. et al. (2015) Burden of Clostridium difficile infection in the United States. N. Engl. J. Med. 372, 825–834.
| Burden of Clostridium difficile infection in the United States.Crossref | GoogleScholarGoogle Scholar | 25714160PubMed |
[6] Spigaglia, P. et al. (2018) Antibiotic resistances of Clostridium difficile. Adv. Exp. Med. Biol. 1050, 137–159.
| Antibiotic resistances of Clostridium difficile.Crossref | GoogleScholarGoogle Scholar | 29383668PubMed |
[7] Toth, M. et al. (2018) Intrinsic class D β-lactamases of Clostridium difficile. MBio 9, e01803-18.
| 30563905PubMed |
[8] Knight, D.R. et al. (2017) Genome analysis of Clostridium difficile PCR ribotype 014 lineage in Australian pigs and humans reveals a diverse genetic repertoire and signatures of long-range interspecies transmission. Front. Microbiol. 7, 2138.
| 28123380PubMed |
[9] Tenson, T. et al. (2003) The mechanism of action of macrolides, lincosamides and streptogramin B reveals the nascent peptide exit path in the ribosome. J. Mol. Biol. 330, 1005–1014.
| The mechanism of action of macrolides, lincosamides and streptogramin B reveals the nascent peptide exit path in the ribosome.Crossref | GoogleScholarGoogle Scholar | 12860123PubMed |
[10] Freeman, J. et al. (2018) The ClosER study: results from a three-year pan-European longitudinal surveillance of antibiotic resistance among prevalent Clostridium difficile ribotypes, 2011-2014. Clin. Microbiol. Infect. 24, 724–731.
| The ClosER study: results from a three-year pan-European longitudinal surveillance of antibiotic resistance among prevalent Clostridium difficile ribotypes, 2011-2014.Crossref | GoogleScholarGoogle Scholar | 29066403PubMed |
[11] Spigaglia, P. et al. (2011) Multidrug resistance in European Clostridium difficile clinical isolates. J. Antimicrob. Chemother. 66, 2227–2234.
| Multidrug resistance in European Clostridium difficile clinical isolates.Crossref | GoogleScholarGoogle Scholar | 21771851PubMed |
[12] Tang-Feldman, Y.J. et al. (2005) Prevalence of the ermB gene in Clostridium difficile strains isolated at a university teaching hospital from 1987 through 1998. Clin. Infect. Dis. 40, 1537–1540.
| Prevalence of the ermB gene in Clostridium difficile strains isolated at a university teaching hospital from 1987 through 1998.Crossref | GoogleScholarGoogle Scholar | 15844079PubMed |
[13] Baines, S.D. and Wilcox, M.H. (2015) Antimicrobial resistance and reduced susceptibility in Clostridium difficile: potential consequences for induction, treatment, and recurrence of C. difficile Infection. Antibiotics (Basel) 4, 267–298.
| Antimicrobial resistance and reduced susceptibility in Clostridium difficile: potential consequences for induction, treatment, and recurrence of C. difficile Infection.Crossref | GoogleScholarGoogle Scholar | 27025625PubMed |
[14] Schmidt, C. et al. (2007) Antimicrobial phenotypes and molecular basis in clinical strains of Clostridium difficile. Diagn. Microbiol. Infect. Dis. 59, 1–5.
| Antimicrobial phenotypes and molecular basis in clinical strains of Clostridium difficile.Crossref | GoogleScholarGoogle Scholar | 17509804PubMed |
[15] Lebel, S. et al. (2004) The cme gene of Clostridium difficile confers multidrug resistance in Enterococcus faecalis. FEMS Microbiol. Lett. 238, 93–100.
| 15336408PubMed |
[16] Linder, J.A. et al. (2005) Fluoroquinolone prescribing in the United States: 1995 to 2002. Am. J. Med. 118, 259–268.
| Fluoroquinolone prescribing in the United States: 1995 to 2002.Crossref | GoogleScholarGoogle Scholar | 15745724PubMed |
[17] McDonald, L.C. et al. (2018) Clinical practice guidelines for Clostridium difficile infection in adults and children: 2017 update by the Infectious Diseases Society of America (IDSA) and Society for Healthcare Epidemiology of America (SHEA). Clin. Infect. Dis. 66, e1–e48.
| Clinical practice guidelines for Clostridium difficile infection in adults and children: 2017 update by the Infectious Diseases Society of America (IDSA) and Society for Healthcare Epidemiology of America (SHEA).Crossref | GoogleScholarGoogle Scholar | 29462280PubMed |
[18] Kaihovaara, P. et al. (1998) Flavodoxin-dependent pyruvate oxidation, acetate production and metronidazole reduction by Helicobacter pylori. J. Antimicrob. Chemother. 41, 171–177.
| Flavodoxin-dependent pyruvate oxidation, acetate production and metronidazole reduction by Helicobacter pylori.Crossref | GoogleScholarGoogle Scholar | 9533458PubMed |
[19] Musher, D.M. et al. (2005) Relatively poor outcome after treatment of Clostridium difficile colitis with metronidazole. Clin. Infect. Dis. 40, 1586–1590.
| Relatively poor outcome after treatment of Clostridium difficile colitis with metronidazole.Crossref | GoogleScholarGoogle Scholar | 15889354PubMed |
[20] Barbut, F. et al. (1999) Antimicrobial susceptibilities and serogroups of clinical strains of Clostridium difficile isolated in France in 1991 and 1997. Antimicrob. Agents Chemother. 43, 2607–2611.
| Antimicrobial susceptibilities and serogroups of clinical strains of Clostridium difficile isolated in France in 1991 and 1997.Crossref | GoogleScholarGoogle Scholar | 10543736PubMed |
[21] Peláez, T. et al. (2008) Metronidazole resistance in Clostridium difficile is heterogeneous. J. Clin. Microbiol. 46, 3028–3032.
| Metronidazole resistance in Clostridium difficile is heterogeneous.Crossref | GoogleScholarGoogle Scholar | 18650353PubMed |
[22] Johnson, S. et al. (2000) Metronidazole resistance in Clostridium difficile. Clin. Infect. Dis. 31, 625–626.
| Metronidazole resistance in Clostridium difficile.Crossref | GoogleScholarGoogle Scholar | 10987742PubMed |
[23] Al-Nassir, W.N. et al. (2008) Comparison of clinical and microbiological response to treatment of Clostridium difficile-associated disease with metronidazole and vancomycin. Clin. Infect. Dis. 47, 56–62.
| Comparison of clinical and microbiological response to treatment of Clostridium difficile-associated disease with metronidazole and vancomycin.Crossref | GoogleScholarGoogle Scholar | 18491964PubMed |
[24] Ammam, F. et al. (2013) The functional vanGCd cluster of Clostridium difficile does not confer vancomycin resistance. Mol. Microbiol. 89, 612–625.
| The functional vanGCd cluster of Clostridium difficile does not confer vancomycin resistance.Crossref | GoogleScholarGoogle Scholar | 23782343PubMed |
[25] Freeman, J. et al.. (2015) Pan-European longitudinal surveillance of antibiotic resistance among prevalent Clostridium difficile ribotypes. Clin. Microbiol. Infect. 21, 248.e9–248.e16.
[26] Knight, D.R. et al. (2016) A phenotypically silent vanB2 operon carried on a Tn1549-like element in Clostridium difficile. mSphere 1, e00177-16.
| 27536735PubMed |
[27] O’Connor, J.R. et al. (2008) Rifampin and rifaximin resistance in clinical isolates of Clostridium difficile. Antimicrob. Agents Chemother. 52, 2813–2817.
| Rifampin and rifaximin resistance in clinical isolates of Clostridium difficile.Crossref | GoogleScholarGoogle Scholar | 18559647PubMed |
[28] Venugopal, A.A. and Johnson, S. (2012) Fidaxomicin: a novel macrocyclic antibiotic approved for treatment of Clostridium difficile infection. Clin. Infect. Dis. 54, 568–574.
| Fidaxomicin: a novel macrocyclic antibiotic approved for treatment of Clostridium difficile infection.Crossref | GoogleScholarGoogle Scholar | 22156854PubMed |
[29] Cornely, O.A. et al. (2014) Clinical efficacy of fidaxomicin compared with vancomycin and metronidazole in Clostridium difficile infections: a meta-analysis and indirect treatment comparison. J. Antimicrob. Chemother. 69, 2892–2900.
| Clinical efficacy of fidaxomicin compared with vancomycin and metronidazole in Clostridium difficile infections: a meta-analysis and indirect treatment comparison.Crossref | GoogleScholarGoogle Scholar | 25074856PubMed |
[30] Järhult, J.D. (2015) One Health: a doctor’s perspective. Vet. Rec. 176, 351–353.
| One Health: a doctor’s perspective.Crossref | GoogleScholarGoogle Scholar | 25837947PubMed |
[31] Blancou, J. et al. (2005) Emerging or re-emerging bacterial zoonoses: factors of emergence, surveillance and control. Vet. Res. 36, 507–522.
| Emerging or re-emerging bacterial zoonoses: factors of emergence, surveillance and control.Crossref | GoogleScholarGoogle Scholar | 15845237PubMed |
[32] Lim, S.C. et al. (2018) Antimicrobial susceptibility of Clostridium difficile isolated from food and environmental sources in Western Australia. Int. J. Antimicrob. Agents 52, 411–415.
| Antimicrobial susceptibility of Clostridium difficile isolated from food and environmental sources in Western Australia.Crossref | GoogleScholarGoogle Scholar | 29802886PubMed |
[33] Slimings, C. et al. (2014) Increasing incidence of Clostridium difficile infection, Australia, 2011-2012. Med. J. Aust. 200, 272–276.
| Increasing incidence of Clostridium difficile infection, Australia, 2011-2012.Crossref | GoogleScholarGoogle Scholar | 24641152PubMed |
[34] Jordan, D. et al. (2009) Antimicrobial use in the Australian pig industry: results of a national survey. Aust. Vet. J. 87, 222–229.
| Antimicrobial use in the Australian pig industry: results of a national survey.Crossref | GoogleScholarGoogle Scholar | 19489779PubMed |
[35] Chopra, I. and Roberts, M. (2001) Tetracycline antibiotics: mode of action, applications, molecular biology, and epidemiology of bacterial resistance. Microbiol. Mol. Biol. Rev. 65, 232–260.
| Tetracycline antibiotics: mode of action, applications, molecular biology, and epidemiology of bacterial resistance.Crossref | GoogleScholarGoogle Scholar | 11381101PubMed |
[36] Jasni, A.S. et al. (2010) Demonstration of conjugative transposon (Tn5397)-mediated horizontal gene transfer between Clostridium difficile and Enterococcus faecalis. Antimicrob. Agents Chemother. 54, 4924–4926.
| Demonstration of conjugative transposon (Tn5397)-mediated horizontal gene transfer between Clostridium difficile and Enterococcus faecalis.Crossref | GoogleScholarGoogle Scholar | 20713671PubMed |
